back to top

    Leading Polish biotech company Bioceltix S.A. to debut on WSE Main Market

    After just ten months since its debut on NewConnect, Wrocław-based Bioceltix S.A. will move to the Main Market of the Warsaw Stock Exchange on Monday (September 5). The co-owner of the rising star of Polish biotechnology is the first graduate of the WSE Growth Academy to join the ranks of CEOs of listed companies.

    In recent years, an increasing number of biotechnology-related brands have decided to make their presence felt on the world’s most important trading floors. This is due to growing investor interest in the dynamic development of this field of science, which brings not only tangible financial returns but also medical breakthroughs. The wave of debuts of successive biotechnology companies is not missing the WSE, the largest stock exchange in Central and Eastern Europe, either.


    “Bioceltix is a team of experts working on innovative therapies for veterinary use. We work on biopharmaceuticals that harness the immunomodulatory properties of mesenchymal stem cells.”


    As Łukasz Bzdzion, co-owner of the company explained at the NewConnect debut: “In animals, as in humans, there is a marked increase in the number of patients suffering from inflammatory and autoimmune diseases. Stem cell-based biological medicines, which Bioceltix is successfully working on, could play a key role in their treatment.”


    “Over 500 clinical studies in various phases that seek to examine the use of mesenchymal stem cells (MSCs) in treating numerous diseases are currently underway worldwide. The immunomodulatory properties of MSC serve as a starting point for developing innovative medical therapies for humans. At Bioceltix, we harness the therapeutic potential of MSC to develop innovative biopharmaceuticals for companion animals focusing on areas with high demand for new therapies. Veterinary medicines, based on the immunomodulatory mechanism of action of MSC, will be an alternative to symptomatic pharmacotherapy focused mainly on alleviating pain and inflammation. Our goal is to create analgesic and anti-inflammatory biopharmaceuticals that will induce the natural mechanisms of regenerating tissues affected by the disease,” we can read on the Bioceltix website


    The company did not conduct a public offering immediately prior to the admission of the shares to trading on the WSE Main Market. In 2020 and 2021, the Issuer conducted two public offerings of series F and G shares before entering the NewConnect market, raising a total of nearly PLN 11 million.


    Łukasz Bzdzion began his adventure with the Warsaw Stock Exchange earlier as a participant in the second edition of the WSE Growth Academy. It is one of the strategic initiatives of #GPW2022, a long-term plan for the development and operation of the Warsaw Stock Exchange. The main objective of the programme is to prepare entrepreneurs and managers theoretically and practically to achieve business success – including on the stock exchange floor.

    More in section